Design, Synthesis, and Investigation of Cytotoxic Effects of 5-Hydroxyindole-3-Carboxylic Acid and Ester Derivatives as Potential Anti-breast Cancer Agents
- PMID: 38116544
- PMCID: PMC10728841
- DOI: 10.5812/ijpr-133868
Design, Synthesis, and Investigation of Cytotoxic Effects of 5-Hydroxyindole-3-Carboxylic Acid and Ester Derivatives as Potential Anti-breast Cancer Agents
Abstract
Breast cancer is a deadly disease with a high prevalence rate among females. Despite several treatments, scientists are still engaged in finding less invasive treatments for this disease. The cellular proliferation rate and cell viability survey are critical to assess the drug's effect on both normal and malignant cell populations. Indole derivatives are promising candidates for their cytotoxic effect causing on breast cancer cells; however, they are less toxic on normal cells. This study synthesized 23 novel 5-hydroxyindole-3-carboxylic acids and related esters featuring various linear, cyclic, and primary aromatic amines. The MTT assay indicated the cytotoxicity of all acid and ester derivatives against the MCF-7 cells with no significant cytotoxicity on normal human dermal fibroblasts cells. Compound 5d, an ester derivative possessing a 4-methoxy group, was the most potent compound, with a half-maximal effective concentration of 4.7 µM. Compounds 5a, 5d, and 5l bearing ester group in their structure demonstrated cytotoxicity values < 10 µM against the MCF-7 cell line and were safe for advanced screening.
Keywords: 5-Hydroxy Indole; Human Breast Cancer Cell Line (MCF-7); MTT Assay; Survivin.
Copyright © 2023, Teymori et al.
Conflict of interest statement
No financial or research support has been used in this article, and the authors of this article are students and faculty members of Shahid Beheshti University and are not employed by any particular organization. This article has no personal financial interest for any of the authors. The authors of this article do not have any kind of shares in any particular company and have not received or given any fees for consulting. This article is not and will not be patented anywhere. There are no personal relationships in this article. Membership without dues in a governmental or non-governmental organization. None of the authors of this article is a member of the editorial board or reviewer of this journal.
Figures
References
-
- Comsa S, Cimpean AM, Raica M. The Story of MCF-7 Breast Cancer Cell Line: 40 years of Experience in Research. Anticancer Res. 2015;35(6):3147–54. - PubMed
LinkOut - more resources
Full Text Sources